Pharmacy Operational Update

In brief · summary, not quotable

MedPal AI plc reported a record May 2026 with over 42,250 prescription items dispensed, surpassing the previous monthly record and bringing the total dispensed since launch to over 250,000. This strong volume growth, coupled with pharmacy gross margins exceeding 34% as previously reported, has resulted in an annualized turnover run rate of over £5 million based on May's performance, indicating significant operational leverage and sustained adoption of their services.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered, integrated digital health and pharmacy company, is pleased to provide an operational update on the continued strong growth in dispensing volumes at its wholly owned pharmacy operations.

Record month: over 42,250 prescription items dispensed in May 2026 - the Company's best-performing month since pharmacy operations commenced, surpassing the previous record of 41,000 items, reflecting underlying momentum in patient demand.
Major cumulative milestone: the Company has now dispensed over 250,000 prescription items in total since launch, underscoring the sustained, accelerating adoption of its NHS and private pharmacy services and the Company's dispensing platform retains substantial headroom for further growth.
Strong margins: as reported in the Company's interim results for the six months ended 28 February 2026, pharmacy gross margin strengthened to over 34% as dispensing volumes scaled, reflecting the operational leverage of the Company's automated dispensing model.
Annualised run rate: based on the May 2026 dispensing volume the Company's pharmacy operations are now trading at an annualised turnover run rate in excess of £5 million.

Chief Executive Officer's commentary

Jason Drummond, Founder and Chief Executive Officer of MedPal AI, commented:

"May was our best month yet, with over 42,250 items dispensed, and we have now passed a quarter of a million prescriptions since we began. To reach this scale in such a short period is a powerful validation of our automated, technology-led model - which, as our interim results showed, is delivering pharmacy gross margins of over 34% as we grow. We have built this momentum from a standing start, and with significant capacity still available across our dispensing operations, the Board sees a clear runway for continued, profitable growth."

The Directors of the Company are responsible for the contents of this announcement.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.